NEWS

PRESS RELEASE

Wallaby Medical Inc. announces CE Mark and FDA Clearance of the Avenir™...

Wallaby Medical announces CE Mark approval and FDA 510(k) clearance of its differentiated embolic coil system, the Avenir Coil System. The intended use for the Avenir Coil System is for endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The Avenir Coil System is also intended for arterial and venous embolization in the peripheral vasculature.

PRESS RELEASE

1st Pass Success with NeVa™ "M1S" (4.0 x 22 mm) after failure of 2 diffe...

Watch this clinical case report from a 75 year old female patient presented with NIHSS of 19 presented 4 hours after symptom onset.It was noted that the patient had had a knee implant surgery 3 days prior to her stroke. Additional risk factors included: Coronary Heart Failure, Hypertension, Diabetes, Atrial fibrillation.On admission CT ASPECTS was 10.Imaging confirmed distal left MCA occlusion.

PRESS RELEASE

Medtronic Partners with Viz.ai to Accelerate Adoption of New Artificial...

DUBLIN and SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) - Medtronic plc (NYSE:MDT), a global leader in medical technology, and Viz.ai, the emerging leader in applied artificial intelligence (AI) in stroke care, have partnered to accelerate the adoption of Viz.ai’s new technology, which helps synchronize stroke care and decrease time to treatment, potentially improving outcomes for patients.

PRESS RELEASE

Vesalio obtains additional CE approval for new products, NeVa clinical d...

Nashville, TN, May 22, 2019 Vesalio announces it has obtained its second CE Approval spanning multiple new NeVa™ product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies while also introducing first to market features such as a distal filter.  A controlled launch of the new technology will begin in June in Europe with expected full commercial release in Q4 of this year.

PRESS RELEASE

Vesalio Secures $5 Million Investment Capital Funding

Nashville, TN, May 14, 2019 Vesalio announces it has recently raised $5 million in funding.  The capital will support the continued global expansion of the NeVa™ Neurothrombectomy System, finance key clinical studies and launch new product introductions. 

PRESS RELEASE

Balt USA, LLC Announces CE Mark Obtained for Titan™ Aspiration Catheter

IRVINE, Calif.-- (BUSINESS WIRE )-- Balt USA, LLC announces today it has obtained CE mark for the Titan aspiration catheter. The Titan catheter line consists of a highly navigable, large bore (.070”) aspiration catheter and a smaller bore (.036”) catheter for navigation and support. Obtaining the CE mark for Titan* enhances the Balt stroke portfolio as it will be available alongside the CatchView* revascularization stent, Vasco* catheters, Ballast long sheath and Hybrid guidewires to provide a complete stroke solution to the marketplace.

PRESS RELEASE

MicroVention Announces Positive Safety and Effectiveness Results in WEB-...

The WEB-IT pivotal trial highlights positive clinical outcomes with the WEB® Aneurysm Embolization System, the only intrasaccular flow disruptor approved in the United States.

PRESS RELEASE

"There needs to be active dialogue with physicians to discuss […] what t...

Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market leader. Girin goes on to explain the high key growth strategy he is implementing and the impact that BALT’s products can have on the quickly developing medical field of stroke treatment.

PRESS RELEASE

Vesalio Reports Expansion of International Distributor Network and Strok...

Nashville, TN, April 02, 2019 --(PR.com)-- Vesalio announces it has executed multiple exclusive distribution agreements in Europe, Latin America, Asia and the Middle East and now has market coverage in 39 countries for the NeVa™ Neuro-thrombectomy System.

PRESS RELEASE

Balt International has announced receiving the CE mark for the Ballast ....

Balt International has announced receiving the CE mark for the Ballast .088 Long Sheath. The Ballast .088 Long sheath is indicated for the introduction of interventional devices into peripheral, coronary and neurovasculature. It is a class III medical device which is described as a guiding catheter and as an introducer sheath.The Ballast .088 will be commercially available in different lengths, from 80 cm, via 90 cm and up to a 100 cm long.This new generation sheath is designed with a braided reinforced proximal segment, an optimised progressively softer distal coil segment and a low-profile outer diameter to deliver the right balance between atraumatic navigation and proximal support.With this new Ballast .088 Long sheath, Balt International offers its premium sheath, designed to improve support and navigationPascal Girin, Balt International’s CEO stated, "The clearance of the Ballast .088 Long Sheath is a significant milestone in our global commercialisation efforts and a major step towards delivering a complete portfolio of innovative solutions"."The Ballast .088 Long Sheath represents an advance in technology for physicians around the world. It also is a fantastic representation of the capabilities of the new global Balt, with full R&D teams in both France and the USA developing physician inspired technologies to advance the care of patients with neurovascular diseases" commented Dave Ferrera, Senior VP of Global R&D and CTO of Balt USA.